Real-World Data Validates Venetoclax's Efficacy in CLL Patients After BTK Inhibitor Treatment
核心洞察
A large real-world study of 2,020 CLL (搜索) patients demonstrated 78% objective response rate for venetoclax-based therapy in patients previously treated with BTK inhibitors.
The analysis spanning 23 global centers confirms venetoclax's safety and effectiveness as both monotherapy and in combination with rituximab or obinutuzumab.
The findings provide strong evidence supporting venetoclax as a viable therapeutic option for CLL (搜索) patients who have received prior BTK inhibitor therapy.
A comprehensive real-world study presented at the 2023 American Society of Hematology (搜索) (ASH) Annual Meeting has validated the effectiveness of venetoclax in chronic lymphocytic leukemia (搜索) (CLL (搜索)) patients previously treated with Bruton tyrosine kinase (搜索) inhibitors (BTKi).
The large-scale analysis, encompassing data from 23 centers worldwide, examined 2,020 patients, with 1,287 having received BTKi in a prior line of therapy. Among these, 184 patients initiated venetoclax-based treatment regimens, with 115 receiving venetoclax monotherapy and 69 receiving combination therapy with either rituximab or obinutuzumab.
Treatment Outcomes and Response Rates
The study revealed an impressive objective response rate of 78.0% among the 127 evaluable patients, demonstrating venetoclax's robust efficacy in this patient population. This response rate was observed across both monotherapy and combination therapy groups, providing clinicians with valuable evidence for treatment decision-making.
Clinical Implications for BTKi-Experienced Patients
These findings carry significant implications for CLL (搜索) treatment sequencing, particularly for patients who have previously received BTKi therapy. The data suggests that venetoclax-based regimens represent a reliable therapeutic option in the post-BTKi setting, offering healthcare providers a well-validated treatment alternative.
Treatment Options and Combinations
The study highlighted the flexibility of venetoclax-based therapy, showing effectiveness both as a single agent and in combination with anti-CD20 antibodies. This versatility provides clinicians with multiple treatment approaches to address individual patient needs and circumstances.
The real-world nature of this study adds particular value to its findings, as it reflects outcomes in routine clinical practice rather than the controlled environment of clinical trials. This practical validation strengthens the position of venetoclax in the contemporary CLL (搜索) treatment landscape, especially for patients who have progressed on or after BTKi therapy.